137 results about "Mesenchymal stem cell differentiation" patented technology

Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.

A method for differentiating mesenchymal stem cells of bone marrow into neural cells comprises culturing the mesenchymal stem cells in a medium containing epidermal growth factor(EGF), basic fibroblast growth factor(bFGF) and hepatocyte growth factor(HGF), and the neural cells produced thereby can be employed for the treatment of a neural disease.

A transplant material which is capable of imparting desired mechanical properties, elevating bone tissue repair speed and improving biocompatibility. This transplant material comprises an artificial and biologically inactive material, which is to be implanted in vivo as a substitute for bone tissue, and at least one type of cells selected from among osteoblasts and precursory osteoblasts which are adhered to the surface of the artificial material so that the artificial material is coated with the bone matrix produced by the cells. The artificial material involves not only a biologically inactive material but also a biologically inactive material coated with a biologically active substrate. This transplant material is produced by culturing mesenchymal stem cells collected from a living body to differentiate into at least one type of cells selected from among osteoblasts and precursory osteoblasts and then culturing the cells together with the artificial material to thereby adhere the differentiated cells on the surface of the artificial material and coat the surface of the artificial material with the bone matrix produced by the differentiated cells.

The invention relates to the field of biotechnology, in particular to an inducing method for differentiating umbilical cord mesenchymal stem cells into nerve cells, which comprises the following steps of: cultivating the separated umbilical cord mesenchymal stem cells in an MSC culture medium to spread a whole culture dish; cultivating the stably-subculturing mesenchymal stem cells in the culture dish which is spread with the extracellular matrix by means of the MSC culture medium to be 70% confluence; and leading the 70% confluent mesenchymal stem cells to sequentially pass through four inducing culture mediums to cultivate, wherein the four inducing culture mediums comprise the following factors of 5-azacytidine+Pam3CSK4, bFGF+Noggin, bFGF+RA+FGF8+Wnt3a, and Bmp4+Shh+RA+NGF+BDNF. The inducing method has the benefit effects of being free of chemical substances with cytotoxicity, transgenic technology and nerve cell co-cultivation, and being high in differentiating efficiency and shorter in time consumption.

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.

The present invention relates to a method for inducing differentiation of bone marrow-derived mesenchymal stem cells into mature neurons by culturing them in an optimal medium supplemented with necessary composition. According to the pre-induction method of the invention and a method for inducing differentiation of mesenchymal stem cells into neurons by culturing them in neuronal induction media (NIM) containing butyl hydroxyanisole, forskolin and VPA, mesenchymal stem cells can be effectively differentiated into neurons or motor neurons, which thereby can be effectively used as a therapeutic agent for cell therapy for neurodegenerative diseases.

The purpose is to proliferate a mesenchymal stem cell to a sufficient degree while reducing the amount of blood serum contained in a biological tissue progenitor cell to be grafted, and to efficiently differentiate the mesenchymal stem cell into the biological tissue progenitor cell. There is provided a method for culturing a mesenchymal stem cell, comprising: a first culture step of proliferating a mesenchymal stem cell in a medium containing blood serum; and a second culture step of differentiating the mesenchymal stem cell into a biological tissue progenitor cell in a medium containing blood serum at a lower concentration than that in the medium used in the first culture step.

The invention provides small RNA (shR337) capable of differentiating hematopoietic stem cells (MSC) from human nonhematopoietic stem cells (HSC) such as mesenchymal stem cells (MSC). The discovery of the small RNA also provides an action target capable of differentiating the hematopoietic stem cells from the human nonhematopoietic stem cells such as the bone marrow mesenchymal stem cells. The small RNA can restrict the protein translation of EIDI genes after being transfected to human bone marrow mesenchymal stem cells to transform the human bone marrow mesenchymal stem cells into hematopoietic stem cells with CD45<+>surface antigen positive, and the hematopoietic stem cells with CD45<+>surface antigen positive can be further differentiated into myeloid cells and lymphoid cells. Mice in vivo experiments show that the differentiation of the small RNA to the mesenchymal stem cells is directional and undivided.

The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.

The invention discloses a building method of a pre-revascularizational large biological bone scaffold of a composite cell which is used for the field of biological manufacturing. According to the building method of the pre-revascularizational large biological bone scaffold of the composite cell, composite biological 3D printing, electro-hydro dynamics direct writing, subtractive manufacturing and a cell assembly technology are adopted to build a functional pre-revascularizational network in the interior of the large biological bone scaffold to promote repairing of large bone defect. The key of the building method lies in the fact that sodium alginate which is a biological material and can be degraded in a body is adopted to serve as a sacrificial material, endothelial cells are loaded in the sodium alginate, and the sodium alginate is adhered to the surface of a prefabricated vessel network through migration of the endothelial cells. Meanwhile, the sodium alginate is degraded to form the prefabricated vessel network. In addition, human mesenchymal stem cells in a bone scaffold material are differentiated into osteoblasts, and synthesizes and secretes bone matrix under the mutual promotional effect of the endothelial cells, mineralization is conducted, so that the efficiency of bone tissue repair is improved, the functional problem of large bone tissue repair is solved, and the building method has important significance on solving the large bone tissue repair problem to clinical medicine.

The invention belongs to the technical field of stem cell induction differentiation, particularly relates to an inducer and an induction medium, and discloses an inducer and induced differentiation complete medium for inducing mesenchymal stem cells into nerve cells. The inducer for inducing the mesenchymal stem cells into the nerve cells comprises resveratrol, icariin, hydrocortisone, VEGF, IGF-I and EPO. Every one thousand milliliters of the induced differentiation complete medium for inducing the mesenchymal stem cells into nerve cells comprises 30-50 micromoles of resveratrol, 5-10 micromoles of icariin, 5-10 micromoles of hydrocortisone, 10-20 micrograms of VEGF, 5-10 micrograms of IGF-I, 2-5 micrograms of EPO and the balance mesenchymal stem cell serum-free complete media. According to the induced differentiation complete medium for inducing the mesenchymal stem cells into the nerve cells, the traditional Chinese medicine ingredients of resveratrol and icariin are combined with hydrocortisone and the growth factors of VEGF, IGF-I and EPO to synergistically induce the mesenchymal stem cells to be directionally differentiated into the nerve cells, and the selected induction components are all free of poison, high in induction efficiency, short in induction time, good in activity of the nerve cells obtained through induction, free of rejection after cell transplantation, free of ethical issues and high in safety.

The invention belongs to the field of biomedicine, and relates to an inducer for inducing human adipose derived stromal cells into insulin-secretion cells, an induction medium and a method. The inducer for inducing human adipose derived stromal cells into insulin-secretion cells consists of the following components: a rhodiola rosea injection, nicotinamide, taurine and GLP-1. Every 1,000ml of the induction medium containing the inducer comprises 20-40g of the rhodiola rosea injection, 0.97-1.47g of the nicotinamide, 0.25-0.50g of the taurine, 26.84-40.27mg of the GLP-1 and the balance being a human adipose derived stromal cell serum-free medium, which are mixed uniformly, filtered and degermed. According to the inducer for inducing human adipose derived stromal cells into insulin-secretion cells, the induction medium and the method, differentiation of the human adipose derived stromal cells into the insulin-secretion cells is induced by using the injection of a traditional Chinese medicine, namely, rhodiola rosea, and each component is safe and nontoxic. The method has few steps and is short in time and high in the inducing efficiency.

The invention discloses a method for the directional induction of the differentiation of MSCs. The method for the directional induction of the differentiation of MSCs comprises the following steps: inoculating and adsorbing in-vitro induction cells to the lower surface of a polycarbonate film, inoculating in-vitro MSCs to the upper surface of the polycarbonate film, and co-culturing the induction cells and the MSCs to promote the differentiation of the MSCs to target cells, wherein each of the MSCs and the induction cells cannot pass through the holes of the polycarbonate film. The differentiation of UCMSCs to cuticle cells has a beneficial effect on the clinic skin regeneration research progress in the future. The method develops ideas for the increase of the induction method for the multi-directional differentiation of the MSCs, and provides bases for the construction of tissue engineering skins through adopting the UCMSCs as seed cells.

The invention provides a culture method for inducing mesenchymal stem cell to differentiate for forming osteocyte under the condition without CO2. The culture method comprises the following steps of: culturing the third-generation human mesenchymal stem cell under the conditions of 5 percent of CO2 and 37 DEG C and standing overnight; after the cell is completely attached to the wall and grows until 80 percents of cell is fused, replacing an inductive culture medium and culturing under the conditions of 37 DEG C without CO2 for 14-21 days to obtain osteoblast, wherein the inductive culture medium is formed by adding fetal calf serum, penicillin, streptomycin, hexadecadrol, beta-sodium glycerophosphate and vitamin C in a basal medium and is prepared from the following components calculatedby final concentration: 0.41g/L of sodium bicarbonate, 1.5g/L of disodium hydrogen phosphate dodecahydrate, 0.07g/L of monopotassium phosphate and 8.17g/L of sodium chloride; and solvent of the inductive culture medium is an L-DMEM cell culture medium free of sodium bicarbonate. According to the novel culture medium formula provided by the invention, the mesenchymal stem cell osteoblast can be normally induced to differentiate; the differentiation effect is favorable, so that the consumption of equipment is reduced; and the novel culture medium formula is suitable for cell culture and research on induced differentiation under the condition without CO2.

Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing.

The invention discloses a genetically modified stem cell for cartilage repair treatment as well as a preparation method and application of the genetically modified stem cell, and further provides a pharmaceutical composition containing the stem cell. The stem cells comprise nucleic acid for coding an anti-inflammatory factor and nucleic acid for coding a cartilage repair factor, by simultaneously modifying the mesenchymal stem cells by adopting the anti-inflammatory factor and a factor for promoting cartilage differentiation, the mesenchymal stem cells can be effectively promoted to be differentiated into cartilage, and by comprehensively acting on various immune cells through combination of various factors, and the activity of various immune cells is inhibited, so that the local inflammatory environment problem of cartilage repair of parts such as bones and knees is solved, and the swelling condition of a clinical patient is reduced or decreased when the mesenchymal stem cells are applied to bone and knee repair.

The present invention provides a method of differentiating and proliferating a mesenchymal stem cell into the neural cell by culturing in a medium comprising an epidermal growth factor and a hepatocyte growth factor after confluent culture of the mesenchymal stem cell. The present invention provides more effective method of differentiating and proliferating the mesenchymal stem cell or the mononuclear cell comprising the mesenchymal stem cell into the neural cell with a neuron and an astrocyte in terms of time, efficiency and maturity as compared with conventional methods.

The invention belongs to the technical field of cytobiology and bone tissue engineering, relates to a compound used for treating osteoporosis, and especially relates to an application of raloxifene in mesenchymal stem cell in-vitro osteoblast differentiation. According to the invention, raloxifene is added during a mesenchymal stem cell in-vitro osteoblast differentiation culturing process. With the application, mRNA and protein level expressions of osteoblast differentiation marker genes ALP and BMP2, and calcium ion sedimentation can be increased; and mesenchymal stem cell differentiation towards osteoblast can be promoted. The invention relates to the application of raloxifene in mesenchymal stem cell in-vitro osteoblast differentiation, and in treatments of diseases such as fractures,bone defects, and bone wounds.

The invention relates to the field of stem cells, provides a culture medium for promoting differentiation of mesenchymal stem cells, and is used to solve the problem of low differentiation efficiencyof stem cells into bone cells. The culture medium for promoting differentiation of mesenchymal stem cells provided by the invention comprises 6-8 [mu]g/ml of insulin, 0.03-0.05 [mu]g/ml of transferrin, 0.1-0.3 ng/ml of BMP-4, 8-10 ng/ml of FGF-2, 4-6 ng/ml of growth hormone, 160-200 [mu]g/ml of glutathione, 0.5-2 mM of L-glutamine, 60-80 [mu]M of beta-mercaptoethanol, 0.1-0.5 mM of sodium pyruvate, 0.1-0.15 mM of non-essential amino acids, 10-15 [mu]M of nano ferric oxide, and the balance a DMEM culture medium. No biological serum is added into the culture medium, and a nano oxide is introduced at the same time, so that the culture medium can significantly promote differentiation of the mesenchymal stem cells into bone cells.

The invention relates to the field of biomedicine, in particular to a method for inducing human mesenchymal stem cells to differentiate into insulin-secreting cells in vitro, which includes, according to the technical scheme, constructing recombinant eukaryotic expression plasmids of SRF (serum response factor) gene; preliminarily inducing human mesenchymal stem cells into nestin cells first; further inducing the nestin cells into pancreatic progenitor cells; transfecting an eukaryotic expression vector containing the SRF gene to the cells above; and finally inducing the cells into insulin-secreting cells, wherein the eukaryotic expression vector comprises pEGFP (plasmid enhanced green florescence protein), pcDNA or pCMV. By the method, new seed cell sources for cell therapy of diabetes mellitus are provided, new theoretical and experimental basis is provided for directed induction of mesenchymal stem cells differentiating into insulin-secreting cells and clinical application of the insulin-secreting cells, and new models for drug development and screening related to the insulin-secreting cells are provided.